Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Dec;28(12):556-60.
doi: 10.1002/clc.4960281204.

FilterWire distal embolic protection device for vein graft stenting: initial single-center experience

Daniel M Kolansky  1 , Anand J Shah, Terry Mannion, Ruchira Glaser, John W Hirshfeld Jr, Robert L Wilensky, Howard C Herrmann
Affiliations
Comparative Study

FilterWire distal embolic protection device for vein graft stenting: initial single-center experience

Daniel M Kolansky et al. Clin Cardiol. 2005 Dec.

Abstract

Background: Saphenous vein graft (SVG) intervention is associated with a significant incidence of major adverse cardiac events (MACE) related to distal vessel embolization. The FilterWire distal embolic protection device has recently been approved as an adjunct to SVG intervention. We report here our initial experience in a single center in 30 consecutive patients using this device in SVG stenting.

Hypothesis: This study examined the outcomes and complications associated with these devices, as well as whether proficiency with the devices increased with greater experience and whether there were measurable outcome differences between devices.

Methods: We retrospectively identified all patients in whom a FilterWire device was placed at our hospital between June 2001 and June 2004.

Results: The device was successfully deployed in 29 of 30 patients, and all patients were stented successfully. Overall MACE rate was 6.6%, consistent with reports in larger multicenter clinical trials. Transient decreases in flow were noted while the device was in place in six patients, but improved in five patients with device removal.

Conclusions: This early experience in a single center using FilterWire embolic protection indicates that excellent clinical results can be obtained by the adoption of filter protection for SVG intervention, without evidence for a detrimental learning curve.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Keeley EC, Velez CA, O'Neill WW, Safian RD: Long‐term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001; 38: 659–665 - PubMed
    1. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, Stone GW, Leon MB: Creatine kinase‐MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999; 100: 2400–2405 - PubMed
    1. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky A, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB: Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results. J Am Coll Cardiol 2001; 38: 150–154 - PubMed
    1. de Feyter PJ: Percutaneous treatment of saphenous vein bypass graft obstructions : A continuing obstinate problem. Circulation 2003; 107: 2284–2286 - PubMed
    1. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Baim DS: Incidence and treatment of “no‐reflow” after percutaneous coronary intervention. Circulation 1994; 89: 2514–2518 - PubMed

Publication types